Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
March 8, 2018
Medicon Valley Alliance

MVA-member company, Ascelia Pharma, is considering listing on the stock exchange

According to the Danish CEO of Malmø-based, Ascelia Pharma, Magnus Corfitzen, the company, which has developed a contrast agent, Mangoral, that can replace the controversial agent Omniscan, are considering several options for funding the millions of dollars need for future studies.

MVA-member company, Ascelia Pharma, is considering listing on the stock exchange

According to the Danish CEO of Malmø-based, Ascelia Pharma, Magnus Corfitzen, the company, which has developed a contrast agent, Mangoral, that can replace the controversial agent Omniscan, are considering several options for funding the millions of dollars need for future studies.

According to the Danish CEO of Malmø-based, Ascelia Pharma, Magnus Corfitzen, the company, which has developed a contrast agent, Mangoral, that can replace the controversial agent Omniscan, are considering several options for funding the millions of dollars need for future studies. A listing on the stock exchange is one of the options being considered, Magnus Corfitzen, explains Medwatch in the recently published article. 

Read full interview here

Last updated:
March 8, 2018

Medicon Valley Alliance

Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen. Our 245 members, who together employ approximately 140.000 people, represents the region’s triple helix and include universities, hospitals, human life science business, regional governments and service providers.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

According to the Danish CEO of Malmø-based, Ascelia Pharma, Magnus Corfitzen, the company, which has developed a contrast agent, Mangoral, that can replace the controversial agent Omniscan, are considering several options for funding the millions of dollars need for future studies. A listing on the stock exchange is one of the options being considered, Magnus Corfitzen, explains Medwatch in the recently published article. 

Read full interview here

Last updated:
March 8, 2018

Medicon Valley Alliance

Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen. Our 245 members, who together employ approximately 140.000 people, represents the region’s triple helix and include universities, hospitals, human life science business, regional governments and service providers.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail